趋化因子CXCL14是对乙酰氨基酚诱导的急性肝衰竭不良结局的新型早期预后生物标志物
研究评估血浆CXCL14浓度对乙酰氨基酚过量患者(n=50)的预后价值,发现非存活者CXCL14显著高于存活者(p<0.001)。在急性肝衰竭研究组独立队列(n=80)中验证,CXCL14与MELD的AUC相似(0.778),但CXCL14对死亡或需肝移植的特异性(81.2 vs. 52.6)和阳性预测值(82.4 vs. 65.4)更高。联合MELD与CXCL14获得最佳AUC(0.860)。
要点
- 对乙酰氨基酚过量患者中,非存活者血浆CXCL14显著高于存活者(p<0.001)。
- 验证队列中CXCL14与MELD的AUC均为0.778,但CXCL14特异性(81.2 vs. 52.6)和阳性预测值(82.4 vs. 65.4)更高。
- 联合MELD与CXCL14获得最佳AUC(0.860),CXCL14在患者就诊后早期测量时表现最佳。
核心结论
- 在两个独立的对乙酰氨基酚过量患者队列中,循环CXCL14浓度是预测不良结局的新型早期预后生物标志物,可能有助于指导患者管理决策。
- CXCL14在患者就诊后早期测量时表现最佳,突显其对不良预后早期预警的重要性。
研究设计与样本
- 评估对乙酰氨基酚过量患者(n=50)血浆CXCL14浓度的预后潜力,并在急性肝衰竭研究组独立样本队列(n=80)中验证。
- 结合两个队列,采用机器学习训练/测试方案模拟临床场景。
主要发现
- 发现队列中,非存活急性肝衰竭患者CXCL14显著高于存活者(p<0.001)。
- 逻辑回归和AUROC分析显示,CXCL14优于MELD评分,能更好区分非存活者与存活者。
- 验证队列中,MELD与CXCL14的AUC相似(0.778),但CXCL14对死亡或需肝移植的特异性更高(81.2 vs. 52.6),阳性预测值更高(82.4 vs. 65.4)。
- 联合队列中,CXCL14的AUC优于MELD(0.821 vs. 0.787),联合MELD与CXCL14获得最佳AUC(0.860)。
临床怎么用
- 原文结论指出,CXCL14可能有助于指导对乙酰氨基酚过量患者的管理决策,并在就诊后早期测量时对不良预后具有早期预警价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patients with acetaminophen-induced acute liver failure are more likely to die while on the liver transplant waiting list than those with other causes of acute liver failure. Therefore, there is an urgent need for prognostic biomarkers that can predict the need for liver transplantation early after an acetaminophen overdose. APPROACH AND RESULTS: We evaluated the prognostic potential of plasma chemokine C-X-C motif ligand 14 (CXCL14) concentrations in patients with acetaminophen (APAP) overdose (n=50) and found that CXCL14 is significantly higher in nonsurviving patients compared to survivors with acute liver failure ( p < 0.001). Logistic regression and AUROC analyses revealed that CXCL14 outperformed the MELD score, better discriminating between nonsurvivors and survivors. We validated these data in a separate cohort of samples obtained from the Acute Liver Failure Study Group (n = 80), where MELD and CXCL14 had similar AUC (0.778), but CXCL14 demonstrated higher specificity (81.2 vs. 52.6) and positive predictive value (82.4 vs. 65.4) for death or need for liver transplantation. Next, combining the patient cohorts and using a machine learning training/testing scheme to mimic the clinical scenario, we found that CXCL14 outperformed MELD based on AUC (0.821 vs. 0.787); however, combining MELD and CXCL14 yielded the best AUC (0.860). CONCLUSIONS: We find in 2 independent cohorts of acetaminophen overdose patients that circulating CXCL14 concentration is a novel early prognostic biomarker for poor outcomes, which may aid in guiding decisions regarding patient management. Moreover, our findings reveal that CXCL14 performs best when measured soon after patient presentation to the clinic, highlighting its importance for early warning of poor prognosis.
引用
- Umbaugh DS, Nguyen NT, Curry SC, et al. The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure. Hepatology. 2023. PMID: 37910653. doi:10.1097/HEP.0000000000000665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。